Label-Free Technologies For Drug Discovery

Front Cover
Matthew Cooper, Lorenz M. Mayr
John Wiley & Sons, Feb 11, 2011 - Medical - 352 pages
Over the past two decades the benefits of label-free biosensor analysis have begun to make an impact in the market, and systems are beginning to be used as mainstream research tools in many drug discovery laboratories.

Label-Free Technologies For Drug Discovery summarises the latest and emerging developments in label-free detection systems, their underlying technology principles and end-user case studies that reveal the power and limitations of label-free in all areas of drug discovery.

Label-free technologies discussed include SPR, NMR, high-throughput mass spectrometry, resonant waveguide plate-based screening, transmitted-light imaging, isothermal titration calorimetry, optical and impedance cell-based assays and other biophysical methods. The technologies are discussed in relation to their use as screening technologies, high-content technologies, hit finding and hit validation strategies, mode of action and ADME/T, access to difficult target classes, cell-based receptor/ligand interactions particularly orphan receptors, and antibody and small molecule affinity and kinetic analysis.

Label-Free Technologies For Drug Discovery is an essential guide to this emerging class of tools for researchers in drug discovery and development, particularly high-throughput screening and compound profiling teams, medicinal chemists, structural biologists, assay developers, ADME/T specialists, and others interested in biomolecular interaction analysis.

 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

The Revolution of RealTime LabelFree
Design and Implementation of Vertically Emitting
SPR Screening of Chemical Microarrays
The CellKey System A LabelFree CellBased
Dynamic and LabelFree CellBased Assays Using
Incorporating Transmitted Light Modalities into
Nonradioactive Rubidium Efflux Assay
Expanding the Scope of HTMS Methods
Harnessing Optical LabelFree on Microtiter
Use of LabelFree Detection Technologies in
Novartis Evaluation of the ForteBio Octet RED
The PyramidTV Approach to FragmentBased
Characterisation of Antibodies Against
SPRBased Direct Binding Assays in Drug
Kinetic Binding Mechanisms Their Contribution
ITC More Than Just Binding Affinities

A Novel Multiplex SPR Array for Rapid Screening
Bioph ysicsZLabeIFree Assays in Hit Discovery

Other editions - View all

Common terms and phrases

About the author (2011)

Dr Matthew Cooper, Institute for Molecular Bioscience, University of Queensland, Australia
Dr Cooper is a scientist and entrepreneur. He is Co-Founder and Chief Scientific Officer of Akubio Ltd; and Founder and Managing Director of Cambridge Medical Innovations. He has written more than 60 publications and invited reviews in leading scientific journals including Nature Biotechnology, Nature Cell Biology, and Nature Drug Discovery.

Dr Lorenz M. Mayr, Biology Unit, Protease Platform, Novartis Pharma AG, Basel, Switzerland
Dr Mayer is Head of the Biology Unit at the Protease Platform, Centre of Proteomic Chemistry (CPC), at Novartis Pharma AG with responsibility for target finding and target validation, protein expression, assay development and compound screening and profiling for all protease projects. Dr. Mayr is a member of several editorial and scientific advisory boards and also serves as a member at the Board of Directors of SBS, the Society of Biomolecular Sciences.

Bibliographic information